A district court is allowing Pfizer Inc.'s antitrust suit to go forward to determine if Johnson & Johnson's exclusive contracts with payers for Remicade (infliximab) are legal. It concluded that Pfizer has put forth sufficient information to show it has been injured by J&J's efforts to block market access to its biosimilar Inflectra (infliximab-dyyb).
In an Aug. 10 memorandum denying J&J's motion to dismiss the complaint, Judge C. Curtis Joyner of the US District for the Eastern District of Pennsylvania said Pfizer had...